Background & Objectives: Malassizia furfur (pityrosporum ovale/orbicular) and other related species are ethologic agents of tinea versicolor and pityrosporosis in normal individuals but fungal infections due these yeasts are a major cause of mortality in immunocompromised and cancer patients. Catheter-related fungemia or foliculitis is most common mycoses in immunocompromised cases, but malassezia Spp., has been frequently implicated as the causative agent of peritonitis, septic arthritis, mastitis, and sinusitis and variety ocular infections. In this study we surveyed Pityrosporom ovale in dandruff of patients with leukemia underlying chemotherapy.

  Methods: Over a one year period, 100 scale samples were obtained from 50 patients with leukemia underlying chemotherapy. All samples were stained using Metilin Blue method. In direct microscopic examination, seeing budding yeast cells with certain numbers, (bottle bacillus) on epithelial cells were reported positive sample.

  Results: Pityrosporosis were dtected in %78 patient with Leukemia. Most of patients were range of 21-30 years old (27%), that suffering from increased scale.

  Conclusion: Malassezia fur fur is one of more common noncandidal yeasts causing a variety of fungal infection. This organism is a lipophilic yeast that colonizes superficially in human skin and causes superficial mycoses such as tinea versicolor, rarely catheter– related sepsis, foliculitis and other systemic mycoses. Most reported cases of systemic mycoses due to this yeast have been in neonates or adults with malignancy or immunocompromised patients, who were receiving parenteral lipids via a central vascular catheter, undergo chemotherapy and BMT. As pityrosporosis were positive in over than 82% of studied patients, suggested that for prevention of serious fungal infections and mortality in immunocompromissed patients, it must be considered a suitable anti fungal protocol for these cases such as using shampoo or other drugs containing antifungal agents for treatment of patient underlying chemotherapy.

  Background & Objectives: Consumption of ω3 fatty acids supplementation inhibits oxidative stress injury, increases activity of antioxidant enzymes and decreases lipid peroxidation in gastric cancer patients. In this study, we examined effects of ω-3 fatty acid intakes on oxidative stress in gastric cancer patients undergoing chemotherapy.

  Methods: This double blind clinical trial study was conducted on 30 adult patients (15 cases and 15 controls) with gastric cancer during chemotherapy in Ardabil city in 2010. Case and control groups were selected by randomized allocation. Three grams ω -3 fatty acid supplementation (1.8 g EPA & 1.2 g DHA in 10 g fish oil) and placebo were given case and control groups for 45 days, respectively. Anthropometric indices (weight, height & BMI) were measured. Blood samples were taken and then biochemical factors including triglycerides, total cholesterol, HDL and LDL cholesterol, MDA, and total antioxidants were evaluated at the beginning, middle and end of the study . The data were analyzed by using Paired sample t-test, Independent sample t-test and repeated measures test.

  Results: MDA, Weight and BMI of omega group after intervention were significantly more than control group at the end of the study (p<0.05). Weight and BMI were decreased but serum MDA was significantly increased in control group during the study (p<0.05). Weight, BMI , and total antioxidants were significantly increased in omega group during day 30-45, (p<0.05). There were no significant differences in other biochemical factors at the end of study.

  Conclusion: The present investigation shows administration of ω3 fatty acid supplements to gastric cancer patients during chemotherapy increases the total antioxidants capacity and prevents the enhancement of oxidative stress.

  Background & Objectives: Chemotherapeutics induce side effects in patients with cancer . In animal models the intake of ω₃ fatty acids during chemotherapy can increase the impact of chemotherapy drugs and reduce their side effects . This study was aimed to determine the fish oil�intake on side effects of chemotherapy drugs in patients with gastric cancer.

  Methods: A double blind clinical trial study on 30 adult volunteer patients (15 experiments and 15 controls) with gastric cancer was conducted during chemotherapy in Ardabil, Iran, during 2010-2011 . Experimental and control groups were selected by randomized allocation. About 3 grams ω-3 fatty acid supplementation (1.8 g Eicosapentaenoic acid & 1.2 g Docosapentaenoic acid ) and placebo were given to experimental and control groups for 6 weeks, respectively . Then, the results of data were collected at the beginning, 4 and 6 weeks after intervention of ω3/placebo in both groups and analyzed by using descriptive statistics , Chi -Square , Independent sample t-test and Cochran^,s Q test.

  Results: The results of this study showed that there were significant differences of nausea in both group of patients at the end of 6 weeks (p<0.05). A bdominal cramp and nausea significant ly decreased in experimental group during the study (p<0.05). Hair loss , vomiting and diarrhea were reduced in experimental group during the study, but these differences were not statistically significant . There were no significant differences in vomiting , diarrhea and hair loss between two groups at the end of intervention.

  Conclusion: The present study showed that the intakes of fish oil strongly reduce side effects of chemotherapy drugs such as nausea and abdominal cramp. So, this oil supplementation appears to be harmless and useful in patients with gastric cancer during chemotherapy .